LAL

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
MCI Inc., Shareholder, LDD, Investment, Growth, Sale, Annual general meeting, LAL, Patient, Carolwood Pacific Railroad, Video game

Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.

Key Points: 
  • Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.
  • Gross profit for the fourth quarter of 2023 was $17.7 million or 62% of revenue, an increase of $10.2 million or 138% compared to gross profit of $7.4 million or 46% of revenue for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were $28.5 million, a 27% increase from $22.4 million in the fourth quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.
  • On Wednesday, February 28, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter 2023 and full year 2023 financial results.

New Bioscience Lab Expands Access to Fast, Affordable Bioscience Testing

Retrieved on: 
Thursday, February 29, 2024
ISO, FDA, ISO 17025, Lab, Growth, LAL

MIAMISBURG, Ohio, Feb. 29, 2024 /PRNewswire-PRWeb/ -- Bioscension Laboratory Services (Bioscension) today announced the opening of a full-service bioscience testing lab in Miamisburg, Ohio. The lab, which is built with extensive capacity, offers critical services such as bioburden, protein, total organic carbon (TOC), hemoglobin, and LAL testing at a reduced rate to combat increasing prices and excess demand in the lab testing industry.

Key Points: 
  • Newly Opened Lab in Miamisburg, Ohio, Promises Easier Access to More-Economical Bioscience Testing
    MIAMISBURG, Ohio, Feb. 29, 2024 /PRNewswire-PRWeb/ -- Bioscension Laboratory Services (Bioscension) today announced the opening of a full-service bioscience testing lab in Miamisburg, Ohio.
  • The lab, which is built with extensive capacity, offers critical services such as bioburden, protein, total organic carbon (TOC), hemoglobin, and LAL testing at a reduced rate to combat increasing prices and excess demand in the lab testing industry.
  • Bioscience services such as protein, hemoglobin, TOC, and bioburden testing are essential to the development work of medical technology companies, pharma companies, and others.
  • Many companies, especially smaller ones, have experienced the bottle necks associated with the growth in demand for bioscience testing due to increased FDA requirements and industry growth.

American Vision Partners Now Offering the Light Adjustable Lens, Customized Vision after Cataract Surgery

Retrieved on: 
Thursday, February 8, 2024
IOL, LAL, MD, Cataract, LDD, Toric, Light, Patient, Telescopic sight

PHOENIX, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Barnet Dulaney Perkins Eye Center, an American Vision Partners affiliate, is now offering the Light Adjustable Lens™ from RX Sight, a new intraocular lens that provides the opportunity to adjust and customize vision after cataract surgery.

Key Points: 
  • Barnet Dulaney Perkins Eye Center, an American Vision Partners affiliate, is now offering the Light Adjustable Lens™ from RX Sight, a new intraocular lens that provides the opportunity to adjust and customize vision after cataract surgery.
  • PHOENIX, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Barnet Dulaney Perkins Eye Center, an American Vision Partners affiliate, is now offering the Light Adjustable Lens™ from RX Sight, a new intraocular lens that provides the opportunity to adjust and customize vision after cataract surgery.
  • The Light Adjustable Lens™ (LAL) is an advanced technology lens option for cataract and refractive lens exchange patients.
  • Light Adjustable Lens patients will undergo standard cataract surgery, followed by additional light treatments to achieve their desired vision results.

Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

Retrieved on: 
Monday, January 29, 2024
Health, Medical Devices, General Health, Research, Science, Pharmaceutical, Biotechnology, CRL, Corporation, Septic shock, A-DNA, LAL, Software, Refinement, Blood, BET, RCR, Trillium, Video game

Designed to deliver rapid, quantitative results, the rCR cartridges are pre-loaded with all the reagents required to perform an endotoxin test, eliminating need for preparation of multiple reagents, and reducing the opportunity for technician error.

Key Points: 
  • Designed to deliver rapid, quantitative results, the rCR cartridges are pre-loaded with all the reagents required to perform an endotoxin test, eliminating need for preparation of multiple reagents, and reducing the opportunity for technician error.
  • Historically, endotoxin testing has relied on the Atlantic horseshoe crab, whose blood contains LAL, an aqueous extract of blood cells.
  • Charles River continues to apply the highest scientific standards when offering new and innovative products in its BET portfolio.
  • “The launch of Charles River’s Endosafe® Trillium™ cartridge revolutionizes the way the industry approaches endotoxin testing while strengthening our united commitment to sustainability initiatives.

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance

Retrieved on: 
Sunday, January 7, 2024
MCI Inc., Growth, Investment, LAL, Patient, LDD, Sale

ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.

Key Points: 
  • ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.
  • Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2023, is expected to be $127.2 million.
  • RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million, reflecting growth of approximately 44% to 52% over 2023.
  • Audited full-year 2023 and unaudited fourth quarter 2023 financial results are anticipated to be announced in February 2024.

RxSight, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Sale, Investment, Growth, Patient, LDD, LAL, Video game

The company increased its full-year 2023 guidance range for revenue and gross margin; operating expense guidance was narrowed.

Key Points: 
  • The company increased its full-year 2023 guidance range for revenue and gross margin; operating expense guidance was narrowed.
  • Cash, cash equivalents and short-term investments as of September 30, 2023 were $131.9 million compared to $147.1 million as of June 30, 2023.
  • In the third quarter of 2023, the company raised approximately $11.7 million, net of fees and expenses, through the sale of common stock under its At-the-Market facility.
  • On Thursday, November 9, 2023, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its third quarter 2023 financial results.

T. Hunter Newsom, MD Returns to His Hometown and Joins His Father, Dr. William Newsom of Eye Associates of Gainesville, Bringing Innovative Technologies to Alachua County

Retrieved on: 
Friday, December 15, 2023
ICL, Research, Keratoconus, Patient, University, Collagen, FDA, CXL, Aphakia, Cataract, Mayo Clinic, Lens, EVO, Health, LAL, Telescopic sight, Hunting, Dentistry, MD, LASIK, Ophthalmology

GAINESVILLE, Fla., Dec. 15, 2023 /PRNewswire-PRWeb/ -- T. Hunter Newsom, MD, a distinguished Tampa-based ophthalmologist and founder of Newsom Eye, has returned to his hometown of Gainesville, Florida, and is adding a new location, Eye Associates of Gainesville. Dr. T. Hunter Newsom brings a wealth of expertise in advanced eye care, including the pioneering Light Adjustable Lens and Collagen Cross-Linking (CXL) for keratoconus patients, and will be working alongside his father, William Newsom, MD.

Key Points: 
  • T. Hunter Newsom, MD, a board-certified ophthalmologist, specializes in cataract, LASIK surgery, and the EVO Implantable Contact Lens (ICL) procedures.
  • T. Hunter Newsom, MD, alongside his wife Stacy Newsom, both alumni of the University of Florida, cherish deep ties with the community.
  • Under T. Hunter Newsom MD's leadership, Newsom Eye has been at the forefront of ophthalmological advancements, participating in multiple FDA studies.
  • The collaboration between T. Hunter Newsom, MD and Eye Associates of Gainesville marks a new chapter in providing top-tier eye care in the region.

RxSight, Inc. Educational and Product Announcements for AAO 2023

Retrieved on: 
Thursday, November 2, 2023
LAL, MD, AAO, American Academy, American Academy of Ophthalmology, Annual general meeting, LDD, Patient

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco.

Key Points: 
  • ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco.
  • These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229).
  • For the full program of events taking place at AAO 2023, click here .
  • RxSight’s reconfigured Light Delivery Device (LDD™) will also be on display during AAO.

Global Cell and Gene Therapy Manufacturing QC Market Expected to Reach $10.65 Billion by 2033, Witnessing a CAGR of 16.85% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 16, 2023
Biotechnology, Genetics, Health, Gene, QC, NGS, Sartorius AG, Chromatography, Merck Group, MEA, Medicine, Research, Mass spectrometry, ELISA, Organization, Information International, Inc., CAR, QRM, Thermo Fisher Scientific, Patient safety, Flow cytometry, Kidney, Cell, PAT, LAL, Center for Urban and Regional Analysis, Electrophoresis, Therapy, Benchmarking, Eurofins Scientific, PCR, Safety, Automation, LATAM, Fine chemical, Pharmaceutical industry

The "Cell and Gene Therapy Manufacturing QC Market - A Global and Regional Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy Manufacturing QC Market - A Global and Regional Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global cell and gene therapy manufacturing QC market was valued at $1.95 billion in 2022 and is projected to reach $10.65 billion by 2033, with a CAGR of 16.85% during the forecast period from 2023 to 2033.
  • The demand for QC in cell and gene therapy manufacturing is driven by the growing production of therapies and increasing approvals for cell and gene therapies.
  • The global cell and gene therapy manufacturing QC market is on a growth trajectory, and key players are leveraging advancements in technology to drive improvements in product quality and safety.